

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

November 2, 2017

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated November 2, 2017 titled "Zydus' Neshar Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus' Neshor Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

The product will be manufactured at the Neshor's manufacturing facility in the US

Ahmedabad, November 2, 2017

Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the USFDA to market Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets in strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg. The drug is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy and will be produced at the Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA.

The sales of Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets are estimated at \$416.5 million. (Source: IMS Health, IMS National Sales Perspective Audit, MAT September 2017, extracted November 2017)

The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.